Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Promising results have been reported for patients with high-risk hematologic malignancies undergoing HLA-haploidentical bone marrow transplantation (haploBMT) with posttransplantation cyclophosphamide (PTCy), but there are few data on outcomes with myeloablative conditioning in this context. We report the results of a single-institution, prospective phase 2 trial of myeloablative haploBMT using busulfan-based or total body irradiation-based conditioning in 96 children or adults (median age, 42 years; range, 1-65 years) with high-risk hematologic malignancies. Recovery of neutrophils and platelets occurred at a median of 24 and 29 days. Engraftment of donor cells with chimerism .95% was achieved in 91%. The cumulative incidence of acute graft-versus-host disease (GVHD) grades II to IV and grades III to IV at day 100 was 11% and 4%, and of chronic GVHD at 6 and 12 months was 4% and 15%, with 6% moderate to severe. The cumulative incidence of nonrelapse mortality was 6% at 100 days and 11% at 1 year (19% in those aged .55 years). The cumulative incidence of relapse at 1 year was 35%; at 3 years, it was 43%. In multivariable analysis, relapse was associated with increased age (P 5 .02 for age 20-55 years and P 5 .02 for age .55 years) and with minimal residual disease before transplantation (P 5 .05). The overall survival at 1 and 3 years is 73% and 54%, and event-free survival at 1 and 3 years is 57% and 49%. We show that haploBMT with PTCy after myeloablative conditioning is safe and efficacious for adult and pediatric patients with hematologic malignancies. Careful consideration must be given to using myeloablative conditioning in patients age .55 years. This trial was registered at www.clinicaltrials.gov as #NCT00796562.

Original languageEnglish (US)
Pages (from-to)3913-3925
Number of pages13
JournalBlood Advances
Volume4
Issue number16
DOIs
StatePublished - Aug 25 2020

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults'. Together they form a unique fingerprint.

Cite this